Improved detection of early acute, late acute, and occult Hepatitis B infections by an increased sensitivity HBsAg assay

Kuhns, Mary C.; Holzmayer, Vera; McNamara, Anne L.; Sickinger, Eva; Schultess, Jan; Cloherty, Gavin

doi:10.1016/j.jcv.2019.08.001

Cited by 20 publications

(23 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It can be detected in the cells of patients with acute hepatitis B, CHB, HBsAg carrying, liver cirrhosis, and primary hepatocellular carcinoma. Although it could be used as the earliest evidence of HBV infection, it lacked specificity in distinguishing acute and chronic hepatitis [14]. The key to persistent liver damage in CHB patients lied in the continuous replication of the HBV DNA virus.…”

Section: Discussionmentioning

confidence: 99%

Correlation Between HBV Infection Status, Level of Surface Antigen-antibody and Phospholipid Metabolism, Insulin Resistance

Li¹,

Chan²,

Liu³

et al. 2021

AJIM

View full text Add to dashboard Cite

Background: Chronic HBV infection has a continuous effect on blood sugar and blood phospholipid metabolism.Metabolic syndrome (MS) and insulin resistance (IR) are the main risk factor leading to diabetes and cardiovascular disease. At present, the relationship between chronic HBV infection and MS was still controversial. Objective: To explore the correlation between hepatitis B virus (HBV) infection status, level of surface antigen-antibody and phospholipid metabolism, insulin resistance (IR). Methods: A retrospective analysis was performed on the clinical data of 423 patients who underwent hepatitis B markers test in the hospital from January 2017 to June 2019. Among them, there were 95 cases with positive hepatitis B surface antigen (HBsAg) in the HBV infection positive group and 328 cases with negative HBsAg in the HBV infection negative group. The serum phospholipid fatty acid maps and IR related indexes were compared between the two groups. The correlation between the level of HBsAg antibody and phospholipid fatty acid maps, IR related indexes were analyzed by Spearman analysis. Results: The levels of saturated fatty acid (SFA) and u-6/u-3 polyunsaturated fatty acid (PUFA) in the HBV infection positive group were higher than those in the HBV infection negative group, while n-6PUFA, n-3PUFA, PUFA, and PUFA/SFA were all lower than those in HBV infection negative group (P<0.05). The levels of fasting blood glucose (FBG) and insulin resistance index (HOMA-IR) in the HBV infection positive group were higher than those in the HBV infection negative group, while fasting insulin (FINS) and islet sensitivity index (ISI) were lower than those in HBV infection negative group (P<0.05). Spearman correlation analysis showed that HBeAg level was positively correlated with SFA, n-6/n-3 PUFA, FBG and HOMA-IR (r=0.381, 0.369, 0.516, 0.453, P<0.001), while negatively correlated with n-3 PUFA, n-6 PUFA, PUFA, PUFA/SFA, FINS and ISI (r=-0.322, -0.306, -0.467, -0.482, -0.465, -0.356, P<0.001). Conclusion: HBV infection may cause changes in the composition of serum phospholipid fatty acid and IR.

show abstract

Section: Discussionmentioning

confidence: 99%

Correlation Between HBV Infection Status, Level of Surface Antigen-antibody and Phospholipid Metabolism, Insulin Resistance

Li¹,

Chan²,

Liu³

et al. 2021

AJIM

View full text Add to dashboard Cite

show abstract

“…Following a wash cycle, pretrigger and trigger solutions are added, and the resulting chemiluminescent reaction is measured as a relative light unit. The ARCHTECT HBsAg NEXT Qualitative assay, as described, ( 29 ) is a CMIA for the qualitative detection of HBsAg in human serum and plasma. Analytic sensitivity at the assay cutoff is 0.005 IU/mL.…”

Section: Methodsmentioning

confidence: 99%

“…Following a wash cycle, pretrigger and trigger solutions are added, and the resulting chemiluminescent reaction is measured as a relative light unit. The ARCHTECT HBsAg NEXT Qualitative assay, as described, (29) *Previously published (in graphic format). (19) Abbreviation: NA, not assessed (see Materials and Methods).…”

Section: Safety and Efficacy Assessmentsmentioning

confidence: 99%

“…The extent of HBsAg reduction during the REP 301 and REP 301‐LTF studies was examined using a high‐sensitivity HBsAg test capable of detecting HBsAg concentrations in serum as low as 0.005 IU/mL. ( 29 ) The role of hepatitis B surface antibody (anti‐HBs) in clearing HBsAg was examined using a research assay for HBsAg/anti‐HBs immune complexes (ICs). Additionally, changes in serum HBV pregenomic RNA (pgRNA) and HBcrAg were evaluated.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Persistent Control of Hepatitis B Virus and Hepatitis Delta Virus Infection Following REP 2139‐Ca and Pegylated Interferon Therapy in Chronic Hepatitis B Virus/Hepatitis Delta Virus Coinfection

Bazinet¹,

Pântea

Cebotarescu

et al. 2020

Hepatol Commun

Self Cite

View full text Add to dashboard Cite

show abstract

“…Recently, ultrasensitive qualitative [ 130 , 131 ] and quantitative [ 132 , 133 ] HBsAg assays have been developed which reduce the limit of detection 10- to 250-fold to approximately 0.2 to 5 mIU/mL. These assays improve detection in the early window period of acute infection [ 130 , 134 ] and in monitoring of patient reactivation or residual, subclinical levels of HBsAg following spontaneous or treatment-associated seroclearance [ 135 , 136 , 137 , 138 ].…”

Section: Novel Hbv Biomarkersmentioning

confidence: 99%

Novel Biomarkers of Hepatitis B Virus and Their Use in Chronic Hepatitis B Patient Management

Osiowy

2021

Viruses

View full text Add to dashboard Cite

Even though an approved vaccine for hepatitis B virus (HBV) is available and widely used, over 257 million individuals worldwide are living with chronic hepatitis B (CHB) who require monitoring of treatment response, viral activity, and disease progression to reduce their risk of HBV-related liver disease. There is currently a lack of predictive markers to guide clinical management and to allow treatment cessation with reduced risk of viral reactivation. Novel HBV biomarkers are in development in an effort to improve the management of people living with CHB, to predict disease outcomes of CHB, and further understand the natural history of HBV. This review focuses on novel HBV biomarkers and their use in the clinical setting, including the description of and methodology for quantification of serum HBV RNA, hepatitis B core-related antigen (HBcrAg), quantitative hepatitis B surface antigen (qHBsAg), including ultrasensitive HBsAg detection, quantitative anti-hepatitis B core antigen (qAHBc), and detection of HBV nucleic acid-related antigen (HBV-NRAg). The utility of these biomarkers in treatment-naïve and treated CHB patients in several clinical situations is further discussed. Novel HBV biomarkers have been observed to provide critical clinical information and show promise for improving patient management and our understanding of the natural history of HBV.

show abstract

Improved detection of early acute, late acute, and occult Hepatitis B infections by an increased sensitivity HBsAg assay

Cited by 20 publications

References 10 publications

Correlation Between HBV Infection Status, Level of Surface Antigen-antibody and Phospholipid Metabolism, Insulin Resistance

Correlation Between HBV Infection Status, Level of Surface Antigen-antibody and Phospholipid Metabolism, Insulin Resistance

Persistent Control of Hepatitis B Virus and Hepatitis Delta Virus Infection Following REP 2139‐Ca and Pegylated Interferon Therapy in Chronic Hepatitis B Virus/Hepatitis Delta Virus Coinfection

Novel Biomarkers of Hepatitis B Virus and Their Use in Chronic Hepatitis B Patient Management

Contact Info

Product

Resources

About